MEDINDIA
English
हिन्दी
Español
français
中文
The VenaEC biochip is the second generation biochip to Cellix's Vena8(TM)Biochip. As with the first generation Vena8 Biochip, a wide range ofsuspension cell samples may be used with the VenaEC including T-cells,monocytes, neutrophils, eosinophils, platelets and whole blood (heparanized).Compatible with both the VenaFlux(TM) and Microfluidic SP Platforms, theVenaEC Biochip can be used to produce IC50 curves under shear stressconditions mimicking physiological flow. This Biochip is an importantaddition to Cellix's product port folio offering scientists an unique androbust cell-based assay tool for drug discovery, particularly in leadoptimization studies and in parallel with animal models.
"The VenaEC Biochip gives researchers a physiological snap-shot of how apotential lead candidate will affect cells in a human capillary," saidVivienne Williams, CEO of Cellix Ltd. "This is a robust in-vitro cell-basedassay that will give major pharmaceutical and biotechnology companies powerfuldata and a competitive edge on how their lead candidates will perform inclinical trials."
About the VenaEC Biochip
Each VenaEC Biochip comprises one top plate and four substrates easilyassembled in a custom-made frame for inverted microscopes. The top platecontains two microcapillaries which each tissue culture-treated substrateenables the seeding and culturing of a variety of endothelial cells. Minimumcell sample volume is 10mL making it ideal for studying rare cell types or lowsample volumes. Shear stress ranges from 0.05 - 100 dyne/cm2 in steps of 0.05dyne/cm2 using Cellix's Mirus(TM) Nanopump which is part of the VenaFlux(TM)platform. VenaEC Biochips are sold in packs of 10 facilitating 80experiments. Cells derived from different endothelial tissues can be growneasily and successfully on the VenaEC Biochip. Validated examples to dateinclude a Human Coronary Artery Endothelial Cell (HCAEC) monolayer for theinvestigation of monocyte adhesion for cardiovascular diseases and a HumanMicrovascular Endothelial Cell (HMVEC) monolayer for the investigation ofeosinophil adhesion for respiratory diseases.
About Cellix Ltd.
Cellix Ltd. is a privately held instrumentation and cell-based assaycompany developing technologies that accurately mimic cellular behavior invivo for cell-based screening in drug discovery. The Company is headquarteredin Dublin, Ireland, and maintains offices in New York City. For furtherinformation visit www.cellixltd.com.
SOURCE Cellix Ltd.
